Characteristics of Patients Receiving Varenicline Treatment for Smoking Cessation in UK Primary Care–A THIN Database Study

Aug-10

Demographics Pharmacoepidemiology Smoking

AUTHORS : Betina Blak (Details for study: CSD EPIC) now works at AstraZeneca, Horizon Place, 600 Capability Green, Luton, Bedfordshire LU1 3LU, UK – Email: betina.blak@astrazeneca.com

JOURNAL : Pharmacoepidemiology and Drug Safety

REFERENCE: 19(S1):272

DOI : 10.1002/pds.2019

Characteristics of Patients Receiving Varenicline Treatment for Smoking Cessation in UK Primary Care–A THIN Database Study

More publications

Comparative effect of aspirin versus clopidogrel monotherapy on incident type 2 diabetes in patients with atherosclerotic cardiovascular diseases: A target trial emulation study

Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement

Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study